How many insider trades does FilingIQ track for GPCR?

FilingIQ tracks 101 Form 4 insider transactions for GPCR (Structure Therapeutics Inc.), covering filings from Feb 7, 2023 onwards. 22 of those were filed in the last 90 days.

Are GPCR insiders net buyers or net sellers?

Across the full Form 4 history for GPCR, 0 transactions (0%) were open-market purchases and 20 (20%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does GPCR insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is GPCR in?

Structure Therapeutics Inc. (GPCR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.22B.

GPCR insider trading

NasdaqGM Healthcare

Structure Therapeutics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

101

Last 90 days

Buys / sells

0% / 20%

Market cap

$4.22B

About Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Company website: structuretx.com

GPCR insider activity at a glance

FilingIQ has scored 101 insider transactions for GPCR since Feb 7, 2023. The most recent filing in our index is dated Apr 15, 2026.

Across the full history, 0 open-market purchases and 20 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

View live GPCR trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding GPCR

Avoro Capital Advisors LLC

$455.94M · 4.5% of AUM

Logos Global Management LP

$43.20M · 3.5% of AUM

Casdin Capital, LLC

$27.49M · 2.1% of AUM

PRINCIPAL FINANCIAL GROUP INC (PFG)

$23.94M · 1.4% of AUM

Frequently asked

How many insider trades does FilingIQ track for GPCR?: FilingIQ tracks 101 Form 4 insider transactions for GPCR (Structure Therapeutics Inc.), covering filings from Feb 7, 2023 onwards. 22 of those were filed in the last 90 days.
Are GPCR insiders net buyers or net sellers?: Across the full Form 4 history for GPCR, 0 transactions (0%) were open-market purchases and 20 (20%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does GPCR insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is GPCR in?: Structure Therapeutics Inc. (GPCR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.22B.

Methodology & sources

Every GPCR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.